Marilyn J. Lemmon

SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells

Elaine M. Zeman, Jeremy Brown, Marilyn J. Lemmon et al. · International Journal of Radiation Oncology*Biology*Physics · 1986 · 393 citations

High Selective Toxicity, Biochemistry, Redox Regulator +12

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

Leisa Johnson, Annie Shen, Larry Boyle et al. · Cancer Cell · 2002 · 190 citations · Full text

Tumor Biology, Immunology, Antiviral Response +9

Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.

Julia Brown, Marilyn J. Lemmon · PubMed · 1990 · 182 citations

Fractionated Irradiation, Radiation Effect, Cell Death +18

Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.

Mary E. Fox, Marilyn J. Lemmon, Margaret L. Mauchline et al. · PubMed · 1996 · 172 citations

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.

Carla Heise, Marilyn J. Lemmon, David H. Kirn · PubMed · 2000 · 100 citations

Pathology, Tumor Biology, Viral Oncology +18